medigraphic.com
Boletín Médico del Hospital Infantil de México

2007, Number 6

<< Back Next >>

Bol Med Hosp Infant Mex 2007; 64 (6)

Cost of medications by therapeutic group and type at a tertiary care-level pediatric hospital

Jasso-Gutiérrez L, Castellanos-Solis EC, Santos-Preciado JI

Language: Spanish
References: 17
Page: 349-361
PDF size: 160.03 Kb.


ABSTRACT

Introduction. Medication costs exceed the cost of health care. We evaluated the cost variation in medications purchased by our tertiary care-level facility according to therapeutic group and type during 2005 and 2006.
Methods. Using the Mexican Ministry of Health catalogue as a reference, each medication registered in the hospital pharmacy data base was assigned a code by type and therapeutic group. Both unit price as well as total quantities purchased were registered according to the aforementioned catalogue.
Results. The medication costs for 2005 and 2006 were $49 088 923.00 and $58 360 072.00 Mexican pesos, respectively, representing a 15.89% increase over a one-year period. The therapeutic groups representing the highest costs were medications for infectious diseases, electrolyte solutions, and anesthesia. When we considered costs by unit price, a negative variation was observed for drugs in the pulmonary medicine category (-270%) but a positive variation for drugs in the rheumatology group, 10.6%. In 2005, 627 different code numbers were purchased, while these decreased to 534 in 2006. When we analyzed purchases by type, 15 medications accounted for 59.03% of the expenditure in 2005 and 50.60% in 2006. Drugs derived with biotechnology represented the highest unit price.
Conclusions. The increase in the total expenditure of medications purchased by therapeutic group (15.89%) was influenced by the increase in unit price (10.61%), by volumes purchased (12.25%) and by inflation factor.


REFERENCES

  1. Moise P, Docteur E. Pharmaceutical pricing and reimbursement police in Mexico. DELSA/HEA/HWP (2007)1. OECD health data; 2006. p. 4-47.

  2. Hoffman JM, Shah ND, Vermeulen LC, Schumock GT, Grim P, Hunkler RJ, et al. Projecting future drugs expenditures-2007. Am J Health Syst Pharm. 2007; 64: 298-314.

  3. González-Pier E, González-Hernández A. Regulación saludable del sector farmacéutico. Competencia económica México. México, D. F.: Comisión Federal de Competencia; 2004.

  4. Durán AL, Molina ZRE, Jasso GL. Financiamiento y precios de los medicamentos: El caso del IMSS. En: Martínez SH, Villasis KMA, Torres LJ, Gómez DA, editores. Las múltiples facetas de la investigación en salud 4. México D. F.: Instituto Mexicano del Seguro Social; 2005. p. 212-30.

  5. Edición 2006 del Cuadro Básico y Catálogo de Medicamentos. México: Diario Oficial de la Federación. 2ª sección. 11 Diciembre; 2006.

  6. U.S. Food and Drugs Administration. Therapeutic classes. http://www.fda.gov/ohrms/dockets/ac/99/slides/3506s2/tsld022.htm (se accesó 2007 Jul 04).

  7. IMS Health. IMS report U.S. Prescription sales June 8.3 percent in 2006, to 274.9 billion.2007, mar, 8. http://www.imshealth.com/ims/portal/minisite/search/resultsTemplateWrapper/0,2654,6599_40183881,00.html (se accesó 2007 Jul 04).

  8. Jasso GL. Datos personales. Fuente: División de mercados y estudios de fármaco-economía de la Coordinación de Abastecimiento y Equipamiento del Instituto Mexicano del Seguro Social; 2006.

  9. Cavallucci S. What’s making waves in prescriptions sales? IMS Health Canada’s. Comput Script Pharm Pract WEB. 2006, 22: 12. http://www.pharmacygateway.ca/pdfs/2006/12/ppractice_top200_dec06.pdf (se accesó 2007 Jun 28).

  10. Jasso GL. Datos personales. Fuente: Departamento de finanzas. UMAE Hospital de Pediatría del CMN Siglo XXI. México: Instituto Mexicano del Seguro Social; 2006.

  11. Sandullo E. IMS Health, Latin America: Overcoming Economic Challenges. http://www.imshealth.com/web/content/0,3148,64576068_63872702_70260998_71226846,00.html (se accesó Jun 28).

  12. Sandullo E. IMS Health. Vigorous growth returns to Latin America. http://www.imshealth.com/web/content/0,3148,64576068_63872702_70260998_71480777,00.html (se accesó 2007 jun 28).

  13. Reglamento de Insumos para la Salud de la Comisión Federal para la Protección contra Riesgos Sanitarios. México: Artículo 81, Diario Oficial de la Federación, 4 febrero; 1998. p. 64.

  14. Biological Products. Drugs FDA Glossary of Terms. http://www.fda.gov/cder/drugsatfda/glossary.htm (se accesó 2007 jun 28).

  15. Monroe CD, Potter L, Millares M, Barrueta A, Wagner R. Kaiser permanent’s evaluation and management of biotech drugs: assessing, measuring, and affecting use. Health Aff (Millwood). 2006; 25: 1340-6.

  16. Calfee JE, Dupré E. The emerging market dynamics of targeted therapeutics. Health Aff (Millwood). 2006; 25: 1302-8.

  17. IMS Health Canada. Pharmaceutical trends. Top 10 dispensed medications by physician speciality, Canada 2005. http://www.imshealth.com/vgn/images/portal/cit_40000873/43/13/79014586Trends04_En_070610.pdf (se accesó 2007 Jul 8).




2020     |     www.medigraphic.com